Compare Quest Diagnostics Inc (DGX) vs Huntington Ingalls Industries Inc (HII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Huntington Ingalls Industries Inc — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Huntington Ingalls Industries Inc trades at $264.8 (market cap $10.44B). The key difference: Quest Diagnostics Inc is far larger — about 2.4× Huntington Ingalls Industries Inc's market cap, and Huntington Ingalls Industries Inc pays the higher dividend (2.08%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Huntington Ingalls Industries Inc for 28 Days on average.
| DGX | HII | |
|---|---|---|
Market Cap | $25.48B | $10.44B |
Volume | 941,866 | 440,462 |
Sector | Health | Industrials |
52-Week High | $247.45 | $453.73 |
52-Week Low | $173.49 | $257.05 |
Typical Hold Time | 56 Days | 28 Days |
Enterprise Value | $31.23B | $13.37B |
Dividend Yield | 1.49% | 2.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
HII trades at $264.80, up 1.58% today, with a bearish technical signal from moving averages. The company shows solid fundamentals with a P/E of 15.78, net income margin of 5.01%, and a $57.3 billion backlog supporting revenue visibility. Recent contract wins, including a $5.1 billion aircraft carrier overhaul and 10 unmanned vessel orders, highlight operational momentum amid consistent earnings beats.
The outlook is supported by strong defense budgets and execution, but risks include project delays and macroeconomic pressures. Analysts are generally positive with a $363.67 consensus target, implying significant upside, though technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Huntington Ingalls Industries Inc
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →
